Global Action Plan for Influenza Vaccines (GAP) is a comprehensive strategy to reduce the present global shortage of influenza vaccines for seasonal epidemics and pandemic influenza in all countries of the world through three major approaches:
- Increase in seasonal vaccine use
- Increase in vaccine production capacity
- Research and development
GAP was launched in 2006 and further refined in 2011.
The first GAP approach is to encourage countries to increase their seasonal vaccine use.
Increased use of seasonal influenza vaccine will reduce disease burden of seasonal influenza infections, contribute towards the preparedness of countries to respond to an eventual pandemic and motivate industry to develop greater capacity for manufacturing vaccines.
The second GAP approach concentrates on increasing production capacity for pandemic vaccines without expectation for a commensurate increase in the demand for seasonal vaccine.
Short term – produce enough vaccine to immunize two billion people; this vaccine should be available on the market six months after transfer of the vaccine prototype strain to industry.
Medium and long term – produce enough vaccine to immunize the world’s population (6.7 billion).
The third GAP approach encourages to use new technologies to develop more potent and effective influenza vaccines that are:
(a) capable of inducing protective responses after one dose, and/or
(b) induce broad-spectrum and long-lasting immunity against both seasonal and pandemic influenza strains.
16-17 March 2015
Eighth Meeting with International Partners on Prospects for Influenza Vaccine Technology Transfer to Developing Country Vaccine Manufacturers
This year's "Partner's Meeting" was held in Sao Paulo, Brazil and hosted by the Instituto Butantan. The technology transfer programme is a main benefit sharing activity and a key-component under Objective 2 of the GAP programme: increase in vaccine production capacity.
16 - 17 December 2014
Meeting on Live Attenuated Influenza Vaccines in Low and Middle Income Countries
A multidisciplinary expert meeting reviewed available evidence of public health benefits and potentially associated risks of the use of live attenuated influenza vaccines (LAIV) in young children and discussed scientific, regulatory, and ethical perspectives of clinical studies with LAIV in children under 2 years of age.
World Health Organization
Global Action Plan for Influenza Vaccines (GAP)
20, avenue Appia
1211 Geneva 27, Switzerland
Key WHO Information
Director-General and senior management
Governance of WHO
WHO Constitution, Executive Board and World Health Assembly
News, events, fact sheets, multimedia and contacts
International travel and health
Publication on travel risks, precautions and vaccination requirements
World Health Report
Annual report on global public health and key statistics